Remove License Remove Medicine Remove Portfolio
article thumbnail

Pharma stock jumps after signing $50 mil licensing & supply agreement for its biosimilar drug

Trade Brains

Synopsis: Lupin Limited has entered a $50 million licensing and supply agreement with Zentiva to commercialize its biosimilar Certolizumab Pegol across global markets. Lupin has entered into a License and Supply Agreement with Zentiva, k.s., While Zentiva will lead sales in Europe and CIS, Lupin will manage development and supply.

License 59
article thumbnail

Cipla Vs Dr. Reddy’s Laboratories – Financials, Future Plans & More

Trade Brains

It is the world’s largest supplier of generic medicine, in terms of volume with a 20% market share. Following global demand, Cipla has deepened its portfolio for the US markets with continued traction in the respiratory franchise and expansion of its peptide portfolio with increased market share in the Company’s first Lanreotide injection.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

No Fear

Inside Information

The reaction to the online portfolio management solutions (aka the “robos”) generated the same kind of existential chill down the spine that the newfangled software thing did back in the day; people were once again fearful that a computer would replace them. Real advisors didn’t need that fancy stuff.

article thumbnail

Transcript: Marta Norton

The Big Picture

She has a fascinating career, starting a PLS working away up as an analyst and eventually, head of outcome-based strategies for Morningstar, eventually rising from that position and portfolio manager to Chief Investment Officer. Let me give you some background on Morningstar Managed Portfolios. I saw how personal money is.

Portfolio 130
article thumbnail

High EPS Stocks In India – Stocks To Watch In 2023

Trade Brains

Some investors go for high EPS stocks in order to decrease the underlying volatility of their portfolio. Operating Profit Margin 20.20% Page Industries was established in 1994 as a licensed manufacturer, distributor, and marketer of Jockey International’s products in India. 42,500 EPS ₹613 Stock P/E 62.1 RoCE 67.2% RoCE 38.4%

article thumbnail

Fundamental Analysis Of Sun Pharma – Financials & More Details

Trade Brains

These divisions have been arranged geographically and the company has a different product portfolio across these divisions. Sun Pharma in-licensed and commercialised an anti-acne product in the US market. We’ll read more about this in the next section of our fundamental analysis of Sun Pharma. making it a leader in the chronic segment.

article thumbnail

Transcript: Vincent Aita of Cutter Capital

The Big Picture

And by looking at that information and contrasting that with, you know, an independently formulated view that you may have, if there’s an opportunity that arises between the two to play some sort of kind of arbitrage and probabilities in your, in your portfolio construction, that’s the goal of the style of investing we do.